Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Cancer Med. 2024 Jun;13(11):e7375. doi: 10.1002/cam4.7375.
Chimeric antigen receptor T-cell (CAR-T) therapy is becoming an effective technique for the treatment of patients with relapsed/refractory hematologic malignancies. After analyzing patients with tumor progression and sustained remission after CAR-T cell therapy, many factors were found to be associated with the efficacy of CAR-T therapy. This paper reviews the factors affecting the effect of CAR-T such as tumor characteristics, tumor microenvironment and immune function of patients, CAR-T cell structure, construction method and in vivo expansion values, lymphodepletion chemotherapy, and previous treatment, and provides a preliminary outlook on the corresponding therapeutic strategies.
嵌合抗原受体 T 细胞(CAR-T)疗法正在成为治疗复发/难治性血液系统恶性肿瘤患者的有效手段。在分析了 CAR-T 细胞治疗后肿瘤进展和持续缓解的患者后,发现许多因素与 CAR-T 治疗的疗效相关。本文综述了影响 CAR-T 疗效的因素,如肿瘤特征、患者的肿瘤微环境和免疫功能、CAR-T 细胞结构、构建方法和体内扩增值、淋巴细胞耗竭化疗以及既往治疗,并对相应的治疗策略提供了初步展望。